INO

Inovio Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.38
+0.11
+0.47%
After Hours: 23.27 -0.11 -0.47% 19:59 07/10 EDT
OPEN
23.13
PREV CLOSE
23.27
HIGH
23.65
LOW
22.65
VOLUME
16.85M
TURNOVER
--
52 WEEK HIGH
33.79
52 WEEK LOW
1.915
MARKET CAP
3.70B
P/E (TTM)
-19.9897
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average INO stock price target is 22.33 with a high estimate of 45.00 and a low estimate of 8.00.

EPS

INO News

More
Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?
Motley Fool · 2h ago
Could Buying Inovio Pharmaceuticals Stock Make You Rich?
Motley Fool · 2h ago
Bill Gates calls for COVID-19 drugs to go where needed, not 'highest bidder'
Seeking Alpha - Article · 3h ago
Coronavirus Vaccine Race: Moderna or Inovio?
Motley Fool · 1d ago
In the Race to a Coronavirus Vaccine, Buy Moderna Stock or Inovio Stock?
Motley Fool · 3d ago
Covid-19 Research Update: The Stars and the Question Marks
GuruFocus.com · 3d ago
Moderna completes enrollment in mid-stage study of COVID-19 vaccine
In a post on social media, Moderna (MRNA +2.0%) announces that it has completed enrollment in a Phase 2 clinical trial evaluating the safety, reactogenicit
seekingalpha · 3d ago
Core Portfolio Half Year Review - Current Recession Created One Of The Best Investment Opportunities
Seeking Alpha - Article · 3d ago

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About INO

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
More

Webull offers kinds of Inovio Pharmaceuticals Inc stock information, including NASDAQ:INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.